Tradestie Institutional Equity Comparison Engine
CRSP vs ADMA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ADMA Overall Edge
ADMA Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ADMA Biologics, Inc. (ADMA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus ADMA at 15.7x Forward P/E and 44.9% operating margin (+5.1% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ADMA sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ADMA
CRSP 23.4x vs ADMA 15.7x Fwd P/E
Growth & Margin Winner
ADMA
Op Margin -2058.6% vs 44.9% ยท YoY +1325.1% vs +5.1%
Momentum & Technical Winner
ADMA
1Y -20.5% vs -12.8% ยท 52W Pos 1% vs 49%
Options & Structure Winner
ADMA
BREAKDOWN (52nd %ile IV) vs SURGE (8th %ile IV)
CRSP
NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap
$4.1B
1M Return
-17.54%
1Y Return
-20.54%
Forward P/E
23.4x
Unified AI Score
48.6 / 100
HOLD
Tech 33.0
Fund 51.0
Flow 68.0
Mom 60.0
ADMA
NASDAQ
ADMA Biologics, Inc.
Biological Products, (No Disgnostic Substances)
$13.70
+0.11% 1D
Market Cap
$2.9B
1M Return
+28.23%
1Y Return
-12.77%
Forward P/E
15.7x
Unified AI Score
26.5 / 100
SELL
Tech 15.0
Fund 35.0
Flow 66.0
Mom 25.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRSP -20.54%
ADMA -12.77%
Spread: +7.77 pp (ADMA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | ADMA Revenue | CRSP Op. Margin | ADMA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $20M | -5087.8% | -354.9% | ADMA |
| FY2019 | $290M | $30M | 16.1% | -141.1% | CRSP |
| FY2020 | $0M | $40M | -49295.5% | -153.8% | ADMA |
| FY2021 | $910M | $80M | 40.8% | -72.1% | CRSP |
| FY2022 | $0M | $150M | -56190.4% | -25.5% | ADMA |
| FY2023 | $370M | $260M | -60.0% | 8.4% | ADMA |
| FY2024 | $40M | $430M | -1250.4% | 32.6% | ADMA |
| FY2025 | $0M | $510M | -18933.6% | 37.5% | ADMA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | ADMA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $2.9B | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | 23.4x | 17.2x | Lower Multiple | ADMA |
| Forward P/E Ratio Valuation | 23.4x | 15.7x | Lower Multiple | ADMA |
| Revenue Growth (YoY) Growth | +1325.1% | +5.1% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | 44.9% | Higher Margin | ADMA |
| Net Profit Margin Profitability | 0.0% | 35.1% | Higher Margin | ADMA |
| Return on Equity (ROE) Capital Efficiency | -25.6% | 41.9% | Higher ROE | ADMA |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 49% ($7โ$20) | Stronger Trend | ADMA |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | -0.42ฮฒ ยท 99% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 26.5 / 100 (SELL) | Higher Composite | CRSP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRSP vs ADMA Buy Guide
CRSP
BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
52nd %ile
IV Regime
Balanced (25thโ60th %ile)
ADMA
SURGE
7d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRSP nor ADMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.